IDEXX LABORATORIES INC DE
For the period ended Sep 30, 2024. Filed Oct 31, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 31, 2024
IDXX$706.65+4.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023
CONDENSED CONSOLIDATED BALANCE SHEETS
| September 30, 2024 | December 31, 2023 | |
|---|---|---|
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $308,636 | $453,932 |
| Accounts receivable, net | 511,250 | 457,445 |
| Inventories | 389,804 | 380,282 |
| Other current assets | 224,054 | 203,595 |
| Total current assets | 1,433,744 | 1,495,254 |
| Long-Term Assets: | ||
| Property and equipment, net | 717,745 | 702,177 |
| Operating lease right-of-use assets | 121,053 | 115,499 |
| Goodwill | 412,071 | 365,961 |
| Intangible assets, net | 106,885 | 84,500 |
| Other long-term assets | 559,268 | 496,534 |
| Total long-term assets | 1,917,022 | 1,764,671 |
| TOTAL ASSETS | $3,350,766 | $3,259,925 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current Liabilities: | ||
| Accounts payable | $110,603 | $110,643 |
| Accrued liabilities | 511,047 | 478,712 |
| Credit facility | 250,000 | 250,000 |
| Current portion of long-term debt | 99,140 | 74,997 |
| Current portion of deferred revenue | 38,434 | 37,195 |
| Total current liabilities | 1,009,224 | 951,547 |
| Long-Term Liabilities: | ||
| Deferred income tax liabilities | 5,658 | 7,235 |
| Long-term debt, net of current portion | 524,758 | 622,883 |
| Long-term deferred revenue, net of current portion | 26,773 | 28,533 |
| Long-term operating lease liabilities, net of current portion | 103,420 | 99,671 |
| Other long-term liabilities | 62,879 | 65,526 |
| Total long-term liabilities | 723,488 | 823,848 |
| Total liabilities | 1,732,712 | 1,775,395 |
| Commitments, Contingencies and Guarantees (Note 16) | ||
| Stockholders’ Equity: | ||
| Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 107,705 shares in 2024 and 107,506 shares in 2023; Outstanding: 82,037 shares in 2024 and 83,032 shares in 2023 | 10,770 | 10,751 |
| Additional paid-in capital | 1,646,363 | 1,569,565 |
| Deferred stock units: Outstanding: 60 units in 2024 and 59 units in 2023 | 5,885 | 5,530 |
| Retained earnings | 5,116,289 | 4,444,571 |
| Accumulated other comprehensive loss | (75,971) | (71,206) |
| Treasury stock, at cost: 25,669 shares in 2024 and 24,474 shares in 2023 | (5,085,282) | (4,474,681) |
| Total stockholders’ equity | 1,618,054 | 1,484,530 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $3,350,766 | $3,259,925 |
| The accompanying notes are an integral part of these condensed consolidated financial statements. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.